<DOC>
	<DOCNO>NCT02944019</DOCNO>
	<brief_summary>In order understand risk benefit edoxaban use real-world clinical set Non-valvular Atrial Fibrillation ( NVAF ) indication , Daiichi-Sankyo propose post-authorization safety study ( PASS ) gain insight safety ( bleed , liver adverse event , all-cause mortality drug relate adverse event ) edoxaban use patient NVAF preselected .</brief_summary>
	<brief_title>Edoxaban Treatment Routine Clinical Practice Patients With Non Valvular Atrial Fibrillation</brief_title>
	<detailed_description>Patients 12 different European country care setting ( primary secondary care different specialty ) . A one-year patient recruitment period per country plan , could longer patient recruitment number reach . Patient data document baseline ( BL ) , one annual data documentation point four-year follow ( FU ) , final assessment . Patients permanently discontinue edoxaban observation period continue follow annually two year , end observational period ( whichever come first ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>NVAFpatients treat edoxaban accord Summary Product Characteristics ( SmPC ) . Written inform consent participation study ( ICF ) . Not simultaneously participate interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nonvalvular Atrial Fibrillation</keyword>
	<keyword>Post Authorisation Safety Study</keyword>
	<keyword>Safety</keyword>
	<keyword>Real World Evidence</keyword>
</DOC>